Institutional Investors Are Selling Regulus Therapeutics Inc (NASDAQ:RGLS)

June 16, 2018 - By Maria Brooks

Regulus Therapeutics Inc. (NASDAQ:RGLS) Logo

Sentiment for Regulus Therapeutics Inc (NASDAQ:RGLS)

Regulus Therapeutics Inc (NASDAQ:RGLS) institutional sentiment decreased to 1.11 in 2018 Q1. Its down -0.05, from 1.16 in 2017Q4. The ratio is negative, as 20 institutional investors opened new and increased holdings, while 18 reduced and sold stakes in Regulus Therapeutics Inc. The institutional investors in our partner’s database reported: 50.71 million shares, down from 53.17 million shares in 2017Q4. Also, the number of institutional investors holding Regulus Therapeutics Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 8 Reduced: 10 Increased: 11 New Position: 9.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company has market cap of $74.07 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. It currently has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

The stock increased 4.41% or $0.03 during the last trading session, reaching $0.71. About 182,999 shares traded. Regulus Therapeutics Inc. (NASDAQ:RGLS) has declined 45.33% since June 16, 2017 and is downtrending. It has underperformed by 57.90% the S&P500.

Analysts await Regulus Therapeutics Inc. (NASDAQ:RGLS) to report earnings on August, 7. They expect $-0.16 earnings per share, up 60.98 % or $0.25 from last year’s $-0.41 per share. After $-0.15 actual earnings per share reported by Regulus Therapeutics Inc. for the previous quarter, Wall Street now forecasts 6.67 % negative EPS growth.

Bvf Inc Il holds 1.02% of its portfolio in Regulus Therapeutics Inc. for 13.97 million shares. Nea Management Company Llc owns 10.99 million shares or 0.35% of their US portfolio. Moreover, Rhenman & Partners Asset Management Ab has 0.04% invested in the company for 492,878 shares. The California-based Ascend Capital Llc has invested 0.03% in the stock. South Dakota Investment Council, a South Dakota-based fund reported 1.78 million shares.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Ratings analysis reveals 40% of Regulus’s analysts are positive. Out of 5 Wall Street analysts rating Regulus, 2 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $1 while the high is $4.0. The stock’s average target of $1.67 is 135.21% above today’s ($0.71) share price. RGLS was included in 8 notes of analysts from December 20, 2017. The rating was maintained by Wedbush with “Buy” on Monday, March 12. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given on Thursday, May 17 by Wedbush. BMO Capital Markets maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) rating on Thursday, March 8. BMO Capital Markets has “Market Perform” rating and $1.37 target. On Wednesday, December 20 the stock rating was maintained by Wedbush with “Buy”. The company was maintained on Thursday, February 8 by Wedbush. The rating was initiated by FBR Capital with “Hold” on Tuesday, March 27.

Another recent and important Regulus Therapeutics Inc. (NASDAQ:RGLS) news was published by which published an article titled: “New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus …” on June 12, 2018.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: